Curated News
By: NewsRamp Editorial Staff
November 05, 2026
Kairos Pharma Wins 2026 Biotech Breakthrough Award for ENV-105
TLDR
- Kairos Pharma won the 2026 Biotech Breakthrough Award, positioning ENV-105 as a first-in-class CD105 antibody with promising Phase 2 prostate cancer data.
- ENV-105 is a neutralizing antibody targeting CD105 to reverse drug resistance, evaluated with apalutamide in a Phase 2 trial showing significant progression-free survival benefit.
- Kairos Pharma's ENV-105 aims to restore effectiveness of existing cancer treatments, potentially improving outcomes for patients with metastatic prostate and lung cancers.
- Kairos Pharma's ENV-105 (carotuximab) earned the 2026 Cancer Immunology Solution of the Year award for its novel approach to overcoming treatment resistance.
Impact - Why it Matters
This news matters because it highlights a promising approach to one of oncology’s toughest challenges: drug resistance. ENV-105’s mechanism—targeting CD105 to restore sensitivity to standard therapies—could potentially extend the benefit of existing treatments for patients with metastatic prostate and lung cancers. The statistically significant progression-free survival improvement seen in the Phase 2 interim analysis offers early clinical validation, and the award from the Biotech Breakthrough Awards adds third-party recognition that may boost investor confidence and accelerate development. For patients, it signals a potential new strategy to overcome resistance; for investors, it underscores Kairos Pharma’s pipeline potential in the competitive immuno-oncology space.
Summary
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming drug resistance in cancer, has been named the recipient of the 2026 Biotech Breakthrough Award for Cancer Immunology Solution of the Year. The award honors the company’s investigational therapy ENV-105 (carotuximab), a neutralizing antibody designed to restore and extend the effectiveness of existing cancer treatments by targeting CD105, a protein linked to resistance and relapse. Kairos is evaluating ENV-105 in combination with standard-of-care therapies for metastatic prostate cancer and non-small cell lung cancer. The recognition comes on the heels of positive interim efficacy data from the company’s ongoing Phase 2 trial of ENV-105 plus apalutamide in patients with metastatic castration-resistant prostate cancer. The interim analysis showed a statistically significant improvement in progression-free survival for patients receiving the combination versus apalutamide alone.
Based in Los Angeles, Kairos Pharma (NYSE American: KAPA) is leveraging structural biology to address immune suppression and treatment resistance. Its lead candidate, ENV-105, aims to reverse resistance by targeting CD105 and thereby restore the efficacy of standard therapies across multiple cancer types. The full press release is available at https://ibn.fm/GnUxn, and investors can find the latest updates in the company’s newsroom at https://ibn.fm/KAPA.
The announcement was distributed by BioMedWire, a specialized communications platform for the biotech, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications. This infrastructure helps private and public companies reach investors, influencers, and the public. For SMS alerts, text “Biotech” to 888-902-4192 (U.S. mobile phones only). More information is available at https://www.BioMedWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma Wins 2026 Biotech Breakthrough Award for ENV-105
